newsfilter
← Latest News
ACCESS Newswire·

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSKInitiated Phase 1 study of cancer